When a pharma team asks "what does ChatGPT say about our brand," it is watching one screen in a building full of them. The consumer engine is where curiosity starts. It is rarely where a prescription gets written. The question that decides revenue is narrower and harder to see: which AI engine is open on the screen, or in the workflow, at the moment a clinician is weighing a therapy. Increasingly, that is not a general-purpose chatbot. It is a clinical-grade answer engine that was built for medicine, cites medical sources, and lives at or near the point of care.
This is the landscape problem. A brand can be perfectly visible in exploration and entirely invisible at the decision, and a dashboard that only watches consumer engines will report the first as a win while missing the second entirely.
Two different rooms, two different engines
Physician AI use is no longer a leading-edge behavior. The American Medical Association's 2026 survey on augmented intelligence found that 81% of physicians reported awareness or use of AI in their practice in 2026, up from 66% in 2024, with the share reporting no AI use at all falling from 34% to 19% over the same period. Doximity's 2026 State of AI in Medicine Report, fielded across 3,151 U.S. physicians, found 54% currently using AI in clinical practice, with literature search the single most common use case at 35% in January 2026, up from 22% in April 2025. The behavior is not "asking AI for fun." It is asking AI for evidence.
It helps to picture two rooms.
The first room is exploration. A clinician, a patient, or a caregiver opens ChatGPT, Gemini, Perplexity, Claude, or sees a Google AI Overview, and asks an open question: what are the options for this condition, how does this class of drug work, what do people say about side effects. These consumer engines draw on the broad open web. They are where awareness forms and where first impressions of a category get set.
The second room is the decision. Here the user is a credentialed professional, often mid-workflow, asking a precise clinical question with a patient in front of them. The engines in this room were built for that. OpenEvidence reports that it is used daily, on average, by more than 40% of physicians in the United States, supporting over 8.5 million clinical consultations by verified U.S. physicians per month as of July 2025, a daily-active figure rather than a registration count. Alongside it sit other clinical-facing surfaces such as Doximity GPT, Glass Health, and UpToDate. The defining trait of this room is not the brand of the engine. It is what the engine treats as a trustworthy source.
The engines cite different things, and that is the whole point
A consumer LLM and a clinical engine answering the same question are not just two phrasings of the same answer. They are reading from different shelves.
This shows up in the citation behavior, which is the part that matters most for a regulated brand. A peer-reviewed real-life assessment of LLM chatbots in health care, published in Mayo Clinic Proceedings: Digital Health, scored engines on the authenticity of their cited references. The clinical engine OpenEvidence scored 100% on reference authenticity, with no reference hallucination, while consumer ChatGPT modes drew the highest dissatisfaction for the real source of references. The dividing line the study actually documents is grounding behavior: whether the engine systematically attaches real, checkable references, not merely whether it sounds confident.
The risk on the consumer side is well measured. A comparative analysis in the Journal of Medical Internet Research found hallucinated references in 28.6% of GPT-4 outputs and 39.6% of GPT-3.5 outputs when generating citations, rising to 91.4% for the Bard model tested. Those figures are task-specific to unconstrained reference generation, not a universal "answer engine error rate," but they make the structural point: an engine that invents a plausible citation can name your brand, attach a mechanism, and cite a study that does not exist, all in one fluent paragraph.
So the two rooms differ on the one axis a pharma brand cannot ignore. The exploration room runs on the open web, where your label competes with forums, old press, and competitor-funded content. The decision room runs on curated medical evidence, where your label competes with guidelines, trial data, and product monographs. A message that reads fine in the first room can be absent, or subtly wrong, in the second.
Where the global view confirms it
This is not a U.S.-only pattern, and it is not confined to consumer curiosity. An IQVIA analysis of an EPG survey found that 54% of HCPs were already using generative AI tools to access scientific information, with 38% rating it as critical or very important as a source, and 72% of users saying it helps them make better treatment decisions. When most of the prescribers in your market treat a generative engine as a front door to evidence, the engine is no longer a marketing channel. It is part of the prescribing pathway.
And the answer itself is the destination. Pew Research found that when Google shows an AI summary, users click a source link inside that summary in just 1% of visits to pages with such a summary. The clinician reads the synthesized answer and acts. The underlying page you worked so hard to get cited is rarely opened. What the engine says is what the audience receives.
The trap: visible in exploration, invisible at the decision
Put the landscape together and a specific failure mode appears. A brand can optimize hard for consumer LLMs, see its name surface in ChatGPT and Perplexity, and conclude it is winning the AI conversation. Meanwhile, in the clinical engines where prescribing-adjacent questions are asked, the same brand is thinly represented, or it is represented by sources it does not control.
Take a fictional therapy, Varigel, in a crowded category. Run a fixed HCP question set across both rooms. On the consumer engines, Varigel is named in a healthy share of answers and the tone is positive. On the clinical engines, the picture inverts: the guideline-grounded answers lean on an older consensus document and a competitor's published trial, and Varigel's approved positioning barely registers. By the consumer scoreboard, the brand is healthy. At the point where a clinician decides, it is losing. A single-engine view would never reveal the gap, because the gap lives between engines.
The constant across every engine is your label
There is one thing that does not change as you move from room to room: the approved label. The indication, the population, the dosing, the fair-balance obligations. Every engine, consumer or clinical, is either consistent with that label or it is not. That is what makes the label the right measuring stick for all of them at once.
It is also the regulatory anchor. FDA's framework requires that prescription drug promotion not be false or misleading and present a fair balance between effectiveness and risk information, revealing material facts. The standard attaches to the communication, not to whoever or whatever authored it. An AI answer that overstates Varigel's benefit and omits a material risk would fail that standard if a brand had written it. The audience cannot tell who wrote it, and neither can a regulator surveying the landscape.
This is why being cited is not the win. Visibility without accuracy is a liability you can measure. In Juncture's Answer Monitor framework, that is the job of Precision of Answer and Risk of Answer, two of the six Core KPIs scored against your approved label. The important nuance for a landscape strategy: Risk of Answer can differ by surface. A clinical engine grounded in guidelines may carry low risk on a given claim while a consumer engine, pulling from the open web, carries high risk on the same claim, or the reverse if your guideline footprint is weak. You cannot assume one number covers both rooms. You measure each engine against the same label and read the differences.
What to monitor, and against what
The practical shift is small to state and large to operate. Stop asking only what the consumer chatbot says. Start with the list of engines the people who prescribe your product actually use, clinical and consumer, and score every one of them against the single approved label. Precision and Risk of Answer tell you whether the mention is safe. Claim Uptake tells you whether your cleared language is the language being echoed. Top References tells you which sources are feeding each engine, which is where the open-web room and the evidence room diverge most sharply.
The reason a single tool can hold both rooms to one standard is the inside-to-outside join. The same approved label that drives a Pre-check on an asset before MLR, and that lives in the Content Intelligence system of record as modular claims, is the label that Answer Monitor scores every engine against on the outside. One label, one standard, both rooms. That join is the Juncture platform: the inside check and the outside monitor are not two products bolted together, they read from the same ground truth.
Watching only the consumer engine is watching the wrong screen. The decision happens where the clinician is, on the engine the clinician trusts, and the only way to know whether your brand holds there is to monitor that engine against the label it is supposed to honor. That is what Answer Monitor is built to do. See /answer-monitor.
Sources
- AMA 2026 Physician Survey on Augmented Intelligence (American Medical Association, March 2026)
- Doximity 2026 State of AI in Medicine Report
- OpenEvidence announces $210M round and reports daily use by more than 40% of U.S. physicians (PRNewswire / OpenEvidence, July 2025)
- Castano-Villegas et al., Arkangel AI, OpenEvidence, ChatGPT, Medisearch: Are They Objectively up to Medical Standards? (Mayo Clinic Proceedings: Digital Health, 2026)
- Chelli et al., Hallucination Rates and Reference Accuracy of ChatGPT and Bard for Systematic Reviews (Journal of Medical Internet Research, 2024)
- IQVIA: The evolution of pharma engagement as AI becomes a front door to medical information (March 2026, citing an EPG survey)
- Pew Research Center: Google users are less likely to click on links when an AI summary appears in the results (July 2025)
- 21 CFR 202.1, Prescription-drug advertisements (Legal Information Institute, mirroring the Code of Federal Regulations)